Prostaglandin E2 content in residual gastric juice reflects endoscopic damage to the gastric mucosa after naproxen sodium administration

American Journal of Gastroenterology

Volumn 91, Issue 5, 1996, Pages 873-878

  Sarosiek, Jerzy ^a   Marcinkiewicz, Marek ^a   Parolisi, Stella ^a   Peura, David A ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; NAPROXEN; PROSTAGLANDIN E2;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; FEMALE; GASTROSCOPY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; STOMACH JUICE; STOMACH MUCOSA LESION; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; GASTROINTESTINAL HEMORRHAGE; METABOLISM; MIDDLE AGED; PATHOLOGY; STOMACH MUCOSA;

ADULT; CROSS-OVER STUDIES; DINOPROSTONE; DOUBLE-BLIND METHOD; FEMALE; GASTRIC JUICE; GASTRIC MUCOSA; GASTROINTESTINAL HEMORRHAGE; GASTROSCOPY; HUMANS; MALE; MIDDLE AGED; NAPROXEN;

EID: 0029664347     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Kimmey MB. NSAID ulcers and prostaglandins. J Rheumatol 1992; 19(Suppl 36):68-73.
2. Cohen MM, MacDonald WC. Mechanism of aspirin injury to human gastroduodenal mucosa. Prostagland Leukotrienes Med 1982;9:241-55.
3. Ligumsky M, Golanska EM, Hansen DG, et al. Aspirin can inhibit gastric mucosal cyclo-oxygenase without causing lesions in rat. Gastroenterology 1983;84:756-61.
4. Kelly RW, Graham BJM, O'Sullivan MJ. Measurement of PGE2 as the methyl oximate by radioimmunoassay using a novel iodinated label. Prostagland Leukotrienes Essential Fatty Acids 1989;37:187-91.
5. Sarosiek J, Yu Z, Namiot Z, et al. Impact of acid and pepsin on human esophageal prostaglandins. Am J Gastroenterol 1994;89:588-94.
6. 2 in patients with reflux esophagitis under the impact of acid and acid/pepsin solutions: Its potential pathogenetic significance. J Clin Gastroenterol 1995;21:268-74.
7. McCarthy D. Nonsteroidal antiinflammatory drug-induced ulcers: Management by traditional therapies. Gastroenterology 1989;96:662-74.
8. Lee M, Cryer B, Feldman M. Dose effects of aspirin on gastric prostaglandins and stomach mucosal injury. Ann Intern Med 1994; 120:184-9.
9. Vane JR, Mitchell JA, Appleton I, et al. Inducible isoforms of cyclooxygenase and nitric-oxide synthase in inflammation. Proc Natl Acad Sci USA 1994;91:2046-50.
10. Meade EA, Smith WL, DeWitt DL. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other nonsteroidal anti-inflammatory drugs. J Biol Chem 1993; 268:6610-4.
11. Oates JA, Wood AJJ. Nonsteroidal antiinflammatory drugs: Differences and similarities. N Engl J Med 1991;324:1716-25.
12. Cryer B, Redfern JS, Goldschmiedt M, et al. Effect of aghing on gastric and duodenal mucosal prostaglandin concentrations in humans. Gastroenterology 1992;102:1118-23.
13. Cryer B, Lee E, Feldman M. Factors influencing gastroduodenal mucosal prostaglandin concentrations: Roles of smoking and aging. Ann Intern Med 1992;116:636-40.
14. Hawkey CJ. Future treatments for arthritis: New NSAIDs, NO NSAIDs, or No NSAIDs? Gastroenterology 1995;109:612-4.
15. Whittle BJR, Lopez-Belmonte J, Moncada S. Regulation of gastric mucosal integrity by endogenous nitric oxide: Interactions with prostanoids and sensory neuropeptides in the rat. Br J Pharmacol 1990;99: 607-11.
16. Guslandi M. Nitric oxide: An ubiquitous actor in the gastrointestinal tract. Dig Dis 1994;12:28-36.
17. Lambrecht N, Trautmann M, Korolkiewicz R, et al. Role of eicosanoids, nitric oxide, and afferent neurons in antacid-induced protection in the rat stomach. Gut 1995;34:329-37.
18. Aadland E, Fausa O, Vatn M. Protection by misoprostol against naproxen-induced gastric mucosal damage. Am J Med 1987;83(suppl 1A):37-40.
19. Graham DY, Agrawal NM, Roth SH. Prevention of NSAID-induced gastric ulcer with misoprostol: Multicentre, double-blind, placebo-controlled trial. Lancet 1988;2:1277-80.
20. Graham DY, White RW, Moreland LW, et al. Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Ann Intern Med 1993;119:257-62.
21. Roth SH. NSAID gastropathy. The central issue. Drugs 1990;40(Suppl 5):25-8.
22. Hopkinson N, Doherty M. NSAID-associated gastropathy-A role for misoprostol. Br J Rheumatol 1990;29:133-6.
23. Sarosiek J, Mizuta K, Slomiany A, et al. Effect of acetylsalicylic acid on gastric mucin viscosity, permeability to hydrogen ion and susceptibility to pepsin. Biochem Pharmacol 1986;35:4291-5.
24. Sarosiek J, Slomiany A, Slomiany BL. Retardation of hydrogen ion diffusion by gastric mucus constituents: Effect of proteolysis. Biochem Biophys Res Commun 1983;113:1053-60.
25. Murty VLN, Sarosiek J, Slomiany A, et al. Effect of lipids and proteins on the viscosity of gastric mucus glycoprotein. Biochem Biophys Res Commun 1984;121:521-9.
26. Sarosiek J, Marshall BJ, Peura DA, et al. Gastroduodenal mucus gel thickness in patients with Helicobacter pylori: A method for assessment of biopsy specimens. Am J Gastroenterol 1991;86:729-34.
27. Sarosiek J, Murty VLN, Nadziejko C, et al. Prostaglandin effect on the physical properties of gastric mucin and its susceptibility to pepsin. Prostaglandins 1986;32:635-46.
28. Bilski J, Sarosiek J, Murty VLN, et al. Enhancement of the lipid content and physical properties of gastric mucus by geranylgeranyl acetone. Biochem Pharmacol 1987;36:4059-65.
29. Slomiany BL, Sarosiek J, Slomiany A. Gastric mucus and the mucosal barrier. Dig Dis 1987;5:125-45.
30. Slomiany BL, Murty VLN, Sarosiek J, et al. Role of associated and covalently bound lipids in salivary mucin hydrophobicity: Effect of proteolysis and disulphide bridge reduction. Biochem Biophys Res Commun 1988;151:1046-53.
31. Namiot Z, Sarosiek J, Rourk RM, et al. Human esophageal secretion: Mucosal response to luminal acid and pepsin. Gastroenterology 1994; 106:973-81.
32. Sarosiek J, McCallum RW. Esophagoprotection by prostaglandins: How far are we from reaching the verdict? Am J Gastroenterol 1995; 90:847-9.
33. Sarosiek J, McCallum RW. The evolving appreciation of the role of esophageal mucosal protection in the pathophysiology of gastroesophageal reflux disease. J Pract Gastroenterol 1994;18:20J-20Q.
34. Marcinkiewicz M, Peura DA, Sarosiek J. The relationship between the content of gastric mucus protective components in gastric juice and endoscopic damage to the gastric mucosa after naproxen sodium administration. Am J Gastroenterol 1995;91:360-5.